Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Characteristics of ACT500 in Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease Complicated With Chronic Hepatitis B

Inclusion Criteria: * The participant fully understands the purpose, nature, methods of the trial, and the potential adverse reactions, voluntarily agrees to participate in this study, and signs the informed consent form. * Male or female participants aged between 18 and 60 years (inclusive) at the time of signing the informed consent form. * Liver fat content ≥10% as assessed by magnetic resonance imaging-proton density fat fraction (MRI-PDFF) during the screening period. * Liver stiffness measurement (LSM) by FibroScan during the screening period meets 8 kPa ≤ LSM \< 12 kPa, or liver biopsy results within 6 months prior to screening show stage F2/F3 liver fibrosis. * Hepatitis B surface antigen (HBsAg) positive for \>6 months at screening, or other evidence of chronic hepatitis B (CHB), with HBV DNA \< 20 IU/mL. * Serum alanine aminotransferase (ALT) \< 5×ULN at screening. * Received nucleos(t)ide analog (NAs) therapy for at least 1 year prior to screening and are currently on stable NA therapy (including entecavir, tenofovir disoproxil fumarate, tenofovir alafenamide fumarate, and tenofovir amibufenamide). Stable NAs therapy is defined as receiving the same treatment regimen within 3 months prior to screening. * Have at least one of the following metabolic disease risk factors: BMI ≥24.0 kg/m\^2, or waist circumference ≥90 cm (male) and ≥85 cm (female); Prediabetes: fasting blood glucose ≥6.1 mmol/L, or glycated hemoglobin (HbA1c) ≥5.7%; History of type 2 diabetes mellit…